Skip to Content
Søg Menu

Norwegian Perspectives on Urogenital Cancer at ESMO 2024

Bjørg Y. Aksnessæther, Consultant, Department of Oncology, Ålesund Hospital, Norway, presented highlights and Norwegian perspectives on urogenital cancer at the Norwegian Evening at ESMO 2024.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Interview With Thomas Powles

Maximizing the Tolerability of Enfortumab Vedotin + Pembrolizumab – The Upcoming New Standard Treatment for Advanced Bladder Cancer

/ Thomas Powles
Blærecancer Play the Video 05:55

PD-1 Inhibitors Have Shown Remarkable Efficacy

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Gastrointestinal Cancer: 14 Years to Reach the Final Conclusion

/ BestPractice Nordic
ESMO24Gastrointestinal cancer

Several Unsettled Questions About Breast Cancer Treatment

/ BestPractice Nordic
ESMO24Brystcancer

Continued Progress for the Treatment of Gynecological Cancer But No Game-Changer

/ BestPractice Nordic
ESMO24Gynækologisk cancer

New Treatment Possibilities Improve Future Outcomes of Lung Cancer

/ BestPractice Nordic
ESMO24Lungecancer

The Choice of Immunotherapy and PARP Inhibitor for Gynecological Cancer

/ BestPractice Nordic
ESMO24Gynækologisk cancer

Ten-Year Survival Data from a Groundbreaking Trial for the Treatment of Metastatic Melanoma

/ BestPractice Nordic
ESMO24Melanom

No Major Breakthroughs in Lung Cancer Compared to ESMO 2023

/ BestPractice Nordic
ESMO24Lungecancer

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top